Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
CL$97.02-1.71(-1.73%)Cresco Labs Reports Third Quarter 2026 Financial Results6:30:05 AM ETGOOGL$283.97+1.37(+0.48%)BRIEF-Alphabet Takes Stake In Qualcomm & Neutron Holdings, Filing Shows6:24:05 AM ETGOOGL$283.97+1.37(+0.48%)UPDATE 1-Alphabet discloses $548 million worth of Qualcomm stake6:21:05 AM ETNVO$40.04-0.26(-0.65%)Novo Nordisk Owns The Oral Weight Loss Market At 7.8x Operating Income6:16:55 AM ETMRVL$145.12+11.80(+8.85%)BUZZ-AI-linked chip stocks attempt a comeback after Thursday's rout6:15:04 AM ETGOOG$283.00+1.13(+0.40%)Alphabet discloses $548 million worth of Qualcomm stake6:13:29 AM ETPLD$127.63-0.88(-0.68%)Dimensional Fund Advisors Ltd. : Form 8.3 - PROLOGIS INC - Ordinary Shares6:10:06 AM ETTSLA$350.23+6.91(+2.01%)Tesla's Cybertruck Is Dying6:09:41 AM ETGOOGL$283.97+1.37(+0.48%)Alphabet discloses $548 million worth of Qualcomm stake6:09:16 AM ETTSLA$350.23+6.91(+2.01%)RIP Cybertruck. Musk Says Tesla Winding Down Production Months After It Was Called The “Biggest Flop In Automotive History”6:08:57 AM ETCOST$1,050.98-14.61(-1.37%)Mapping the Market: Costco has momentum to rally on6:04:58 AM ETAAPL$341.45-2.95(-0.86%)Apple's predictive text restrictions include 'Dictator Trump' and 'Sleepy Joe,' researcher finds6:02:28 AM ETCBRL$67.92-2.35(-3.34%)13 Top Press Releases from October6:02:00 AM ETAMGN$451.28-9.17(-1.99%)Ro launches healthcare research unit, plans to offer data to drugmakers6:00:13 AM ETWFC$84.19-0.61(-0.72%)NEWSMAKER-Wall Street critic Elizabeth Warren could be at the height of her power in new Congress6:00:07 AM ETMETA$606.61+0.94(+0.16%)EU charges TikTok over harmful algorithmic 'rabbit hole' effects6:00:07 AM ETMETA$606.61+0.94(+0.16%)Democrats planning flood of AI bills when they take control of Congress6:00:06 AM ETAMZN$258.65-1.87(-0.72%)What's Going on With Amazon Stock?6:00:01 AM ETPEP$139.89-2.88(-2.02%)PepsiCo Secures Renewal Across Select KFC International Markets6:00:00 AM ETNVDA$190.06+8.46(+4.66%)Nvidia Stock Rises on Dip-Buying: 3 Reasons to Be Optimistic5:55:00 AM ETMCD$272.56-5.48(-1.97%)Here's How Many Shares of McDonald's You'd Need for $2,000 in Yearly Dividends5:47:00 AM ETBAC$49.82+0.01(+0.02%)EMERGING MARKETS-Stocks at seven-month low as AI-led rout hits Asian tech; CEE assets weaken5:43:05 AM ETSPCX$129.20+5.81(+4.71%)Sell alert for SpaceX stock as SPCX targets crash to $1085:42:52 AM ETTSLA$350.23+6.91(+2.01%)RIP the Cybertruck: Elon Musk says Tesla will wind down production of its most polarizing EV5:40:54 AM ET

FENC · NASDAQ

Fennec Pharmaceuticals Inc.

$9.39 +0.02 (+0.21%)

Company overview

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its clinical-stage product candidate is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$329M
Employees
32
Headquarters
Research Triangle Park, NC
Website
fennecpharma.com
CEO
Jeffrey S. Hackman
Listed
September 15, 2017
P/E
-30.58
Dividend yield
0.00%

Company financials

Revenue
$51M
Gross profit
$47M
Operating income
-$5.6M
EBITDA
-$6.7M
Net income
-$8.4M
EPS
-$0.31
Total assets
$71.8M
Total debt
$0.00
Gross margin
92.23%
Net margin
-16.42%
Earnings yield
-3.27%

Revenue segmentation

By product (FY 2020)
By region (FY 2020)

No geographic segmentation.

Showing FY 2020

Price chart

6.298.109.9111.7113.52
FENC 1D NASDAQ O10.42H10.62L9.33C9.37-0.98 (-9.47%)Vol137.83K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
FENCFennec Pharmaceuticals Inc. Press release Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026 GlobeNewswire
FENCFennec Pharmaceuticals Inc. Stock news Adherex Technologies Inc. (NASDAQ:FENC) Stock Now Rated “Moderate Buy” by Sell-Side Analysts Defense World
FENCFennec Pharmaceuticals Inc. Stock news INNOVER. RIVALISER. GAGNER ENSEMBLE. Des maillots de Coupe du monde à l'innovation circulaire, Far Eastern New Century ouvre la voie dans le domaine des textiles durables PRNewsWire
FENCFennec Pharmaceuticals Inc. Stock news Adherex Technologies (NASDAQ:FENC) and SCYNEXIS (NASDAQ:SCYX) Financial Survey Defense World
FENCFennec Pharmaceuticals Inc. Press release Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026 GlobeNewswire
FENCFennec Pharmaceuticals Inc. Stock news Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect? Zacks Investment Research
FENCFennec Pharmaceuticals Inc. Stock news Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript Seeking Alpha
FENCFennec Pharmaceuticals Inc. Stock news Adherex Technologies Q2 Earnings Call Highlights MarketBeat
FENCFennec Pharmaceuticals Inc. Stock news Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates Zacks Investment Research
FENCFennec Pharmaceuticals Inc. Press release Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026 GlobeNewswire
FENCFennec Pharmaceuticals Inc. Stock news Adherex Technologies Inc. (NASDAQ:FENC) Receives Consensus Rating of “Moderate Buy” from Analysts Defense World
FENCFennec Pharmaceuticals Inc. Stock news Is the Options Market Predicting a Spike in Adherex Technologies Stock? Zacks Investment Research
FENCFennec Pharmaceuticals Inc. Press release Fennec Announces Results of Annual Meeting GlobeNewswire
FENCFennec Pharmaceuticals Inc. Stock news Adherex Technologies' PEDMARK Push Targets Larger AYA Market After Record Quarter MarketBeat
FENCFennec Pharmaceuticals Inc. Press release Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting GlobeNewswire
FENCFennec Pharmaceuticals Inc. Stock news Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript Seeking Alpha
FENCFennec Pharmaceuticals Inc. Stock news Adherex Technologies Q1 Earnings Call Highlights MarketBeat
FENCFennec Pharmaceuticals Inc. Stock news Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates Zacks Investment Research
FENCFennec Pharmaceuticals Inc. Press release Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
FENCFennec Pharmaceuticals Inc. Press release Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026 GlobeNewswire
See more
FAQ

Questions about Fennec Pharmaceuticals Inc.

What does Fennec Pharmaceuticals Inc. do?
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its clinical-stage product candidate is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
What is FENC's market cap?
Fennec Pharmaceuticals Inc. (FENC) is a listed stock with a live quote. The latest market cap on this page is $329M.
Where is Fennec Pharmaceuticals Inc. headquartered?
Fennec Pharmaceuticals Inc. is headquartered in Research Triangle Park, NC.
How do I get FENC news from the API?
Call GET /v1/news?tickers=FENC. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does FENC news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for FENC, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the FENC price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs